Clarity Pharmaceuticals: Half Yearly Report and Accounts
Filed with ASX · · 2 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- SECuRE trial update: Another participant with undetectable PSA & negative PSMA PET
- SECuRE trial update
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- Co-PSMA abstract released
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Clarity Pharmaceuticals
- AMPLIFY trial - Target number of participants achieved
- Registrational Phase III AMPLIFY trial: Target number of participants achieved
- Co-PSMA data presented
- Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
- Clarity signs a large-scale Manufacturing Supply Agreement
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals